Jazz concludes merger with Azur Pharma
Forms a specialist in CNS and women’s health products
US drugmaker Jazz Pharmaceuticals Inc has concluded its merger with Azur Pharma to create a specialist biopharmaceutical company called Jazz Pharmaceuticals plc.
The new firm is based in Dublin, Ireland, with operations in Palo Alto, California and Philadelphia, Pennsylvania in the US.
‘As Jazz Pharmaceuticals plc we are a growing, profitable specialist biopharmaceutical company with a diverse portfolio of products in the central nervous system and women's health areas,’ said Bruce Cozadd, chairman and chief executive.
‘We now have a strengthened management team, a broader commercial organisation and an efficient platform for further growth, with resources to build our product portfolio and a future pipeline.’
Jazz Pharmaceuticals plc employs around 430 people, including a commercial organisation focused on four key areas: narcolepsy, severe chronic pain, psychiatry and a diversified portfolio of women's health products.
The firm expects to have revenues of more than US$475m and generate cash of more than $200m in the first 12 months following the closure of the deal.
